News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
AstraZeneca PLC Drug Zibotentan Fails in Prostate Cancer Trial
September 27, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, Sept 27 (Reuters) - AstraZeneca's (AZN.L) experimental prostate cancer pill zibotentan failed to improve survival in a late-stage clinical trial, dealing a fresh blow to the company's oncology pipeline.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
Europe
AstraZeneca Pharmaceuticals LP
MORE ON THIS TOPIC
Podcast
Oral Weight-Loss Race Heats Up as New Data From Lilly, Viking Reset Expectations
August 26, 2025
·
1 min read
·
Jef Akst
Regulatory
Krystal Cuts Melanoma Study of Viral Immunotherapy as FDA ‘Uncertainty’ Muddies Approval Pathway
August 22, 2025
·
2 min read
·
Tristan Manalac
IN PARTNERSHIP WITH CRESSET
Why AI Won’t Save the 90% of Clinical Trials That Still Fail
August 21, 2025
·
1 min read
·
Lori Ellis
Duchenne muscular dystrophy
With Prasad Back at FDA, Capricor To Fight DMD Cardiomyopathy Rejection
August 20, 2025
·
7 min read
·
Heather McKenzie
